{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chhabra M"],"funding":["Hospital for Sick Children Foundation and the Canadian Institutes of Health Research"],"pagination":["e0290185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11414974"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(9)"],"pubmed_abstract":["<h4>Introduction</h4>Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.<h4>Methods and analysis</h4>Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label,"],"journal":["PloS one"],"pubmed_title":["A multi-centre, tolerability study of a cannabidiol-enriched Cannabis Herbal Extract for chronic headaches in adolescents: The CAN-CHA protocol."],"pmcid":["PMC11414974"],"funding_grant_id":["N120-1028"],"pubmed_authors":["Penz E","Drogemoller BI","Weil AG","Lowthian T","Robson-MacKay A","Gordon S","Chhabra M","Alcorn J","Finley GA","Balshaw R","Pohl D","Huntsman RJ","Stewart B","Alidina Z","Irwin SL","Xie W","Blackman S","Birnie KA","Boerner KE","Mbabaali S","Lewis EC","Tsang VWL","Sell E","Chesick-Gordis M","Kelly LE","Zaslawski Z","Wright GEB","Oberlander TF"],"additional_accession":[]},"is_claimable":false,"name":"A multi-centre, tolerability study of a cannabidiol-enriched Cannabis Herbal Extract for chronic headaches in adolescents: The CAN-CHA protocol.","description":"<h4>Introduction</h4>Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.<h4>Methods and analysis</h4>Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label,","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-02T09:21:05.086Z","creation":"2025-04-04T12:54:00.094Z"},"accession":"S-EPMC11414974","cross_references":{"pubmed":["39302982"],"doi":["10.1371/journal.pone.0290185"]}}